Broadly Neutralizing Antibodies to SARS-CoV-2 Provide Novel Insights Into the Neutralization of Variants and Other Human Coronaviruses.

Bajpai, Prashant; Singh, Vanshika; Chandele, Anmol; Kumar, Sanjeev

Bajpai, Prashant; Singh, Vanshika; Chandele, Anmol; Kumar, Sanjeev.

Afiliação

Bajpai P; ICGEB-Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
Singh V; ICGEB-Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
Chandele A; ICGEB-Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
Kumar S; ICGEB-Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.

Front Cell Infect Microbiol ; 12: 928279, 2022.

Article em En | MEDLINE | ID: mdl-35782120

Assuntos

COVID-19; SARS-CoV-2; Anticorpos Amplamente Neutralizantes; Humanos; Testes de Neutralização; Glicoproteína da Espícula de Coronavírus/genética

Palavras-chave

SARS-CoV-2; alphacoronaviruses; betacoronaviruses; broadly neutralizing antibodies; fusion peptide; human coronaviruses; receptor binding domain; stem-helix domain

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Revista: Front Cell Infect Microbiol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google